Related Experiment Video
Updated: Jul 16, 2026

Manipulation of Gene Function in Mexican Cavefish
Published on: April 22, 2019
The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster
M Schürks1, T Kurth, I Geissler
1Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. schuerks@hotmail.com
Abstract:
The risk of cluster headache (CH) is associated with the G-allele of the G1246A polymorphism in the hypocretin receptor 2 (HCRTR2) gene. First-line medication is effective in only about 70-80% of CH patients. We hypothesized that the HCRTR2 G1246A polymorphism is also of pharmacogenetic relevance in CH and may affect treatment response. We performed a prospective cohort study among 184 unrelated White CH patients. While the HCRTR2 1246G allele was significantly associated with CH in this group, treatment outcomes with triptans, oxygen, verapamil and corticosteroids remained unaffected. Our results do not support a role of the HCRTR2 G1246A polymorphism in drug responses in CH.
Related Concept Videos
Sleep-Wake Cycles
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
G-protein Coupled Receptors
Pharmacogenomics: Identification of New Drug Targets